PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463763
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1463763
Key Highlights
The research antibodies & reagents market generated USD 12.0 billion in 2023, and it will touch USD 18.7 billion, with a 6.7% CAGR, by 2030.
The rising need for clinical diagnostics, carrier screening, and new drugs, along with the surging incidence of genetic disorders is aiding the industry's growth.
The swift technological improvement in pharmaceutical platforms, the substantial application of antibodies & reagents in biotechnology & pharmaceutical analyses, and growing funding and initiatives from private and government bodies for large-scale biotechnology projects resulted in the industry expansion.
The rising research activities to produce new medicines, get them into trials and have them approved boost this industry.
Governments are funding in such activities because of the increasing incidence of chronic and infectious ailments, for discovering effective treatments.
Therefore, life sciences research activities have shattered some records in terms of scientific advancements, funding, and the variety and quantity of new medicines that are accessible to patients across the globe.
The market made some ground-breaking contributions during the pandemic of COVID-19 in the form of vaccines and therapeutics, assisted by the effective application of various research antibodies & reagents.
Key Insights
The reagents category accounted for the largest share of the industry in 2023, of approximately 60%, and it will continue this trend throughout this decade.
The growing application of biotechnology and biosciences in the pharmaceutical and healthcare sectors and the increasing biotechnical and pharmaceutical research for finding more effective, new drugs are driving the reagents category.
Primary antibodies led the industry in 2023, with approximately 70% share, and it will remain leading in the coming years.
The growth in the primary antibodies is because of the extensive variety of utilities offered by these antibodies in the R&D space; and the increasing availability of primary antibodies using goats, mice, rabbits, and various other species as hosts.
The oncology category was the largest contributor to the industry in 2023, with approximately 35% share, and it will remain the largest during this decade, because of the increasing incidence of cancer in key geographies.
The mice category led the industry because of the smaller size and high reproduction rate of the antibodies & reagents produced using mouse tissue.
The western blotting category is leading the market because of the extensive accessibility and acceptance of this method in healthcare R&D.
Monoclonal antibodies led the industry, due to the rising count of cancer research projects, which require antibodies with high specificity.
Proteomics was the largest contributor in 2023, with approximately 40% share, and it will further propel at a robust rate in the coming years.
The demand for greater effectiveness when mapping drug-protein and protein-protein interactions is boosting the proteomics category.
North America led the industry in 2023, with a share of approximately 55%, and it will advance at a robust rate in the coming years, owing to the substantial biotechnology and pharmaceutical R&D activities.
APAC will propel at the fastest rate during this decade, owing to the increasing funding from both foreign and domestic healthcare and biotechnology firms in this region.
The research antibodies & reagents industry is dynamic and competitive. Competition is powered by technological improvements, the specific demands of different research areas, and product innovation.